CCL2 and neoplasm: In particular, the targeting of STAT3 reduces the secretion of chemokines involved in myeloid-derived suppressor cell (MDSC) polarization, such as CXCL2, GM-CSF, M-CSF, IL-10, and IL-13, without altering the levels of CCL2 (MCP-1) and CXCL10 (IP-10), leading to improved recruitment of CD8+ T cells and NK cells at the tumor site.